Nucleic acid dioxygenase ALKBH1
positive regulation of gene expression, epigenetic
N<sup>6</sup>-methyladenine DNA Modification in Glioblastoma.
Genetic drivers of cancer can be dysregulated through epigenetic modifications of DNA. Although the critical role of DNA 5-methylcytosine (5mC) in the regulation of transcription is recognized, the functions of other non-canonical DNA modifications remain obscure. Here, we report the identification of novel N<sup>6</sup>-methyladenine (N<sup>6</sup>-mA) DNA modifications in human tissues and implicate this epigenetic mark in human disease, specifically the highly malignant brain cancer glioblastoma. Glioblastoma markedly upregulated N<sup>6</sup>-mA levels, which co-localized with heterochromatic histone modifications, predominantly H3K9me3. N<sup>6</sup>-mA levels were dynamically regulated by the DNA demethylase ALKBH1, depletion of which led to transcriptional silencing of oncogenic pathways through decreasing chromatin accessibility. Targeting the N<sup>6</sup>-mA regulator ALKBH1 in patient-derived human glioblastoma models inhibited tumor cell proliferation and extended the survival of tumor-bearing mice, supporting this novel DNA modification as a potential therapeutic target for glioblastoma. Collectively, our results uncover a novel epigenetic node in cancer through the DNA modification N<sup>6</sup>-mA.